Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Clinical trial NCT06387056 · RECRUITING

Trial details

NCT number: NCT06387056
Sponsor: The First Affiliated Hospital of Xiamen University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Prostate Cancer Oligometastatic Prostate Cancer

Start date: 2024-04-01
Primary completion: 2026-04-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.